{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115679","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.025280+00:00","generated_at":"2026-06-22T04:13:18.815362+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BT8009 Phase II expansion first patient dosed; Phase I dose escalation complete","bullets":["Phase I dose escalation complete; RP2Ds: 5 mg/m2 weekly and 7.5 mg/m2 (2 on, 1 off) selected.","Confirmed RECIST responses in UC and NSCLC; median duration of response not yet reached.","First patient dosed in Phase II expansion; includes cohorts evaluating BT8009 with CPI.","Priority indication: first-line metastatic UC in cisplatin-ineligible patients combined with CPI.","Updated Phase I data from 49 patients to be presented at medical meeting in 1H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115679","json":"https://secwatch.observer/filing/0001104659-22-115679.json","markdown":"https://secwatch.observer/filing/0001104659-22-115679.md","text":"https://secwatch.observer/filing/0001104659-22-115679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922115679/0001104659-22-115679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922115679/tm2229927d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:13:18.815362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}